Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
– Released positive topline data from Phase 1 study of IV rademikibart…
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl…
Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates
Product sales and commercial rights revenues in 2025 increased 90% year-over-year to…
Renewal Fuels, Inc. (OTC: RNWF), Operating as American Fusion, Provides Regulatory and Legal Update
SOUTHLAKE, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Renewal Fuels, Inc. (OTC:…
CORRECTING & REPLACING — MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3…
CGTN: How China’s development path provides a model for global growth
BEIJING, March 4, 2026 /PRNewswire/ -- As China's annual Two Sessions gets…
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Presented positive updated data from the ALLOHA™ Phase 1 heme trial at…
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update
February 24, 2026 16:30 ET | Source: Cardiff Oncology, Inc. Reported positive…
Inotiv Provides Notice Regarding Cybersecurity Incident
February 13, 2026 16:30 ET | Source: Inotiv, Inc. WEST LAFAYETTE, Ind.,…
Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026
Exceeding latest 2025 guidance following a strong performance from both commercial arms…
